Moviprep (Ascorbic Acid, Sodium Ascorbate, Potassium Chloride, Sodium Chloride, Sodium Sulfate Anhydrous, Macr)

Polyethylene glycol 3350 in Moviprep acts as an osmotic polymer that does not get absorbed. It draws water into the intestinal lumen by maintaining an osmotic gradient, while the accompanying electrolytes keep fluid balance stable. The resulting increase in intraluminal water softens stool and accelerates transit, producing an effective bowel cleanse.

The specific dose and administration schedule of Moviprep are determined by the prescribing clinician based on the intended procedure, patient weight, and clinical condition. Healthcare professionals tailor the amount of powder to reconstitute and the timing of consumption to achieve optimal bowel preparation.

The safety of Moviprep in pregnancy or while breastfeeding has not been definitively established. It should only be used if the prescriber judges that the potential benefit for the diagnostic procedure outweighs any possible risk to the fetus or infant. Discuss any concerns with a healthcare provider.

To request Moviprep, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any special handling) and the necessary import documentation.

Compared with traditional polyethylene glycol‑only preparations, Moviprep adds ascorbic acid and electrolytes, which can reduce the total volume of solution needed while maintaining effective cleansing. This may improve patient tolerability, but the choice of agent depends on individual patient factors, procedural requirements and clinician preference.

Moviprep should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the powder from moisture, direct sunlight and extreme temperatures. Do not refrigerate or freeze the product, as this could affect its stability and efficacy.

Moviprep is supplied as a powder that must be dissolved in a specified amount of water to create an oral solution. The patient drinks the solution according to the schedule prescribed by the clinician, usually split into two doses separated by a short interval, while maintaining adequate fluid intake throughout the preparation period.

The most serious risks include severe electrolyte disturbances (such as hyponatraemia, hyperkalaemia), significant dehydration, and renal function deterioration, especially in patients with pre‑existing kidney disease or those taking interacting diuretics. Prompt medical attention is required if symptoms like dizziness, rapid heartbeat, muscle weakness or confusion develop.

Moviprep is contraindicated in individuals with known or suspected bowel obstruction, perforation, severe inflammatory bowel disease flare, or hypersensitivity to any of its components. Patients with uncontrolled electrolyte imbalances, severe renal impairment, or those on certain interacting medications should avoid use unless a prescriber determines it is safe.